Prelude Therapeutics wills sell several million new shares of stock this month to raise $100 million in new capital to fund its drug pipeline studies. | PHOTO COURTESY OF NASDAQ WILMINGTON – Prelude Therapeutics, the clinical-stage precision oncology company, announced Thursday that it’s selling millions of new shares in the publicly
To continue reading this article ...
Subscribe to Delaware Business Times right now and get access to subscriber-only content like this article.
Plus get 24 issues of DBT via print or digital, special bonus issues, and discounted registration for our in-person events.